NEO News and Press, NeoGenomics Inc. From 10/25/23

2023-10-25 06:30:00 ET Summary NeoGenomics, Inc. has caught a bid in recent weeks, reversing off this year's lows. The market has priced a high required rate of return for buying NeoGenomics today, indicating a substantial degree of implied risk. The company's economic charact...

Neo Comprehensive™ - Heme Cancers is a large and comprehensive next-generation sequencing panel with broad coverage of genes associated with blood cancers Early-stage NSCLC Panel - a therapy selection panel providing a comprehensive overview of biomarkers for detecting early-stage lun...

FT. MYERS, FL / ACCESSWIRE / October 17, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced that it will report its third quarter 2023 financial results on Monday, November 6, 2023. Company management will host a w...

2023-10-17 09:15:48 ET Palm Beach, FL – October 17, 2023 – FinancialNewsMedia.com News Commentary – Multiple myeloma is a type of cancer that affects plasma cells, which are a type of white blood cell that produces antibodies to fight infections. The US mult...

2023-08-09 05:26:49 ET Summary NeoGenomics reported an 18% YoY increase in Q2 revenues, driven by stronger test unit economics in pricing and volumes. The company's revised FY'23 guidance and positive sentiment in its stock are potentially bullish factors. However, concerns ab...

2023-08-08 15:35:17 ET NeoGenomics, Inc (NEO) Q2 2023 Earnings Conference Call August 8, 2023 08:30 ET Company Participants Kendra Sweeney - Vice President, Investor Relations Chris Smith - Chief Executive Officer Jeff Sherman - Chief Financial Officer Vishal...

2023-08-08 07:07:29 ET NeoGenomics press release ( NASDAQ: NEO ): Q2 Non-GAAP EPS of -$0.05 beats by $0.06 . Revenue of $146.92M (+17.5% Y/Y) beats by $9.49M . Clinical Services revenue increased 17% to $123M Advanced Diagnostics revenue increased 22% to $2...

Second Quarter Revenue Increased 18% to $147 Million FORT MYERS, FL / ACCESSWIRE / August 8, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the " Company " ), a leading oncology testing services company, today announced its second-quarter results for the period ended June 30, 2023 as compared to Ju...

2023-08-07 12:45:23 ET NeoGenomics ( NASDAQ: NEO ) is scheduled to announce Q2 earnings results on Tuesday, August 8th, after market close. The consensus EPS Estimate is -$0.11 (+31.3% Y/Y) and the consensus Revenue Estimate is $137.43M (+9.9% Y/Y).Over the last 2 years, NEO...

FT. MYERS, FL / ACCESSWIRE / July 27, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, announced today that the Molecular Diagnostics Services Program (MolDx) has conveyed coverage for the RaDaR® assay, a personalized liquid biopsy for minimal residual dis...